Effect of 4-week Dihydrocapsiate Ingestion on Resting Metabolic Rate
NCT ID: NCT00999297
Last Updated: 2015-11-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
79 participants
INTERVENTIONAL
2008-07-31
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sugar pill (Placebo o mg/d)
0 mg/d sugar pill
Dihydrocapsiate
Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
Dihydrocapsiate
Drug 3 mg/d or 9 mg/d including Placebo
Dihydrocapsiate
Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
3 mg/d or 9 mg/d Dihydrocapsiate
Drug including Placebo
Dihydrocapsiate
Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dihydrocapsiate
Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
Dihydrocapsiate
Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
Dihydrocapsiate
Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy as assessed by medical history and standard medical exam
* Weight-stable
* Body mass index of 25 to 34.9 kg/m2
* Non-smoker
* Sedentary lifestyle: not being physically active grater than 3 days/week for 20 min each time for the previous 6 months, and not participating in regular resistance exercise.
Exclusion Criteria
* Special diet or food aversiions to common foods
* Has allergy to chilli pepper
* Eating chilli peppers on a daily basis
* Usually consuming more than 2 cups of tea or coffee/day
* Usually consuming more than 4 cans of caffeinated soft drinks a day
* Usually consuming more than 3 standard alcohol drinks/day
* Regular use of medications (weight loss drugs, drugs affecting energy metabolism, drugs for depression)
* Usual intake of illicit substances
* Claustrophobia
* Participating or having participated in another clinical trial during the last 4 weeks prior to the beginning of this study
20 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ajinomoto USA, INC.
INDUSTRY
Pennington Biomedical Research Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Eric Ravussin
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eric Ravussin, PhD
Role: PRINCIPAL_INVESTIGATOR
Pennington Biomedical Research Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pennington Biomedical Research Center
Baton Rouge, Louisiana, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Galgani JE, Ryan DH, Ravussin E. Effect of capsinoids on energy metabolism in human subjects. Br J Nutr. 2010 Jan;103(1):38-42. doi: 10.1017/S0007114509991358. Epub 2009 Aug 12.
Galgani JE, Ravussin E. Effect of dihydrocapsiate on resting metabolic rate in humans. Am J Clin Nutr. 2010 Nov;92(5):1089-93. doi: 10.3945/ajcn.2010.30036. Epub 2010 Sep 8.
Related Links
Access external resources that provide additional context or updates about the study.
Effect of capsinoids on energy metabolism in human subjects
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PBRC28016
Identifier Type: OTHER
Identifier Source: secondary_id
PBRC 28016
Identifier Type: -
Identifier Source: org_study_id